日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis

在类风湿性关节炎、银屑病关节炎和强直性脊柱炎的upadacitinib临床试验项目中,主要不良心血管事件(MACE)和静脉血栓栓塞症(VTE)的发生率。

Charles-Schoeman, Christina; Choy, Ernest; McInnes, Iain B; Mysler, Eduardo; Nash, Peter; Yamaoka, Kunihiro; Lippe, Ralph; Khan, Nasser; Shmagel, Anna K; Palac, Hannah; Suboticki, Jessica; Curtis, Jeffrey R

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials

接受乌帕替尼治疗的类风湿性关节炎患者带状疱疹的发生率和危险因素:六项 III 期临床试验的汇总分析

Winthrop, Kevin L; Nash, Peter; Yamaoka, Kunihiro; Mysler, Eduardo; Khan, Nasser; Camp, Heidi S; Song, Yanna; Suboticki, Jessica L; Curtis, Jeffrey R

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

在对生物制剂类疾病修饰抗风湿药物反应不足的类风湿关节炎患者中,upadacitinib 与 abatacept 的患者报告结局:一项 3 期试验的 12 周和 24 周结果

Bergman, Martin; Tundia, Namita; Martin, Naomi; Suboticki, Jessica L; Patel, Jayeshkumar; Goldschmidt, Debbie; Song, Yan; Wright, Grace C

Correction: Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

更正:在对生物制剂类疾病修饰抗风湿药反应不足的类风湿关节炎患者中,upadacitinib 与 abatacept 的患者报告结局:一项 3 期试验的 12 周和 24 周结果

Bergman, Martin; Tundia, Namita; Martin, Naomi; Suboticki, Jessica L; Patel, Jayeshkumar; Goldschmidt, Debbie; Song, Yan; Wright, Grace C

Marked epithelial to mesenchymal transition in surgical margins of oral cancer-an in vitro study

口腔癌手术切缘的显著上皮向间质转化——一项体外研究

Milos Lazarevic, Maja Milosevic, Drago Jelovac, Sanja Milenkovic, Zvezdana Tepavcevic, Federica Baldan, Tijana Suboticki, Bosko Toljic, Dijana Trisic, Miroslav Dragovic, Giuseppe Damante, Jelena Milasin

Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate

对于早期类风湿关节炎且对甲氨蝶呤反应欠佳的患者,阿达木单抗联合甲氨蝶呤治疗或继续甲氨蝶呤单药治疗后疾病活动度和结构进展的预测因素

Smolen, Josef S; van Vollenhoven, Ronald F; Florentinus, Stefan; Chen, Su; Suboticki, Jessica L; Kavanaugh, Arthur